NCT01771458 - A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer | Biotech Hunter

Enrollment

742

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions

Reccurent/Metastatic Solid Tumor Disease

Interventions

DRUG

Targeted therapy based on molecular profiling : Imatinib

PROCEDURE

Tumor biopsy

DRUG

Standard Chemotherapy

DRUG

Targeted therapy based on molecular profiling : Everolimus

DRUG

Targeted therapy based on molecular profiling : Vemurafenib

DRUG

Targeted therapy based on molecular profiling : Sorafenib

DRUG

Targeted therapy based on molecular profiling : Erlotinib

DRUG

Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab

DRUG

Targeted therapy based on molecular profiling : Dasatinib

DRUG

Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)

DRUG

Targeted therapy based on molecular profiling : Abiraterone

Trial Locations (8)

13009

Institut Paoli Calmettes, Marseille

21079

Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc, Dijon

31052

Institut Claudius Régaud, Toulouse

44000

Institut de cancérologie de l'Ouest Centre René Gauducheau, Saint-Herblain

54500

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

69373

Centre Leon Berard, Lyon

75248

Insitut Curie, Paris

92210

Institut Curie Hopital Rene Huguenin, Saint-Cloud

All Listed Sponsors

lead

Institut Curie

OTHER